Medical/Pharmaceuticals News & Press Release Distribution

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with theJoan & Sanford I Weill Medical College of Cornell University in the United States, to launch ...

2021-06-15 22:00 11508

Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

BOSTON, June 15, 2021 /PRNewswire/ -- QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of the Eur...

2021-06-15 18:00 2801

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-06-15 12:00 4971

iAPPS Health Group, a Fin-MedTech company, announces former Senior Minister of State for Health Dr. Lam Pin Min as its Chairman

SINGAPORE, June 15, 2021 /PRNewswire/ -- iAPPS Health Group ("iHG") announced the appointment of former Senior Minister of State for Health, Dr. Lam Pin Min, as Chairman of its board of directors. Dr. Lam Pin Min brings with him a wealth of relevant experience as a veteran in the healthcare...

2021-06-15 09:35 3233

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 15, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...

2021-06-15 09:06 2207

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 14, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...

2021-06-15 08:46 1568

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., June 15, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational Ne...

2021-06-15 07:39 17861

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

* 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest * 91% efficacy in high-risk populations * 100% efficacy against variants "not considered Variants of Concern/Interest" * All COVID-19 hospitalizations/death occurred in the placebo group * Company...

2021-06-15 07:06 5897

BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

VANCOUVER, British Columbia, June 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has d...

2021-06-15 04:19 15838

GENinCode Announces Major US Commercialisation Partnership With EVERSANA

OXFORD, England, June 15, 2021 /PRNewswire/ -- GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC ("EVERSANA") as its launch and commercialisation partner t...

2021-06-15 03:14 1493

Chinese biotech firm Vazyme to showcase full range of COVID-19 Testing Solutions at Medlab

DUBAI, UAE, June 14, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme will showcase a rich lineup of products at the 2021 Medlab Middle East, a leading medical laboratory exhibition co-located with Arab Health. The live in-person event is scheduled to take place from 21 to24 June, 2021 a...

2021-06-14 15:00 2569

Chinese biotech firm Vazyme to showcase full range of COVID-19 Testing Solutions at Medlab

Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis

SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). Th...

2021-06-14 06:00 2445

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in bothChina and the U.S. on May 28 2021 and June 11 20...

2021-06-12 11:16 3489

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of Foot and Mouth Disease Virus in Bovine, Swine and Ovine

The Tetracore® Real-Time PCR Test was validated for use on epithelial and serum samples ROCKVILLE, Md., June 12, 2021 /PRNewswire/ -- Tetracore announced today the licensing of their VetAlert™ Foot and Mouth Disease Virus (FMDV) RNA Diagnostic Test Kit by the United States Department of Agricult...

2021-06-12 06:27 6489

United Imaging Splashes Out at SNMMI 2021 With Clinical and Preclinical Technologies, Total-body AI, and Award-Winning Business Programs

HOUSTON, June 11, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment celebrating its tenth anniversary, announced a number of featured products and is highlighting several distinguished speakers at this year's SNMMI, where it is a Silver S...

2021-06-11 20:10 2217

United Imaging Splashes Out at SNMMI 2021 With Clinical and Preclinical Technologies, Total-body AI, and Award-Winning Business Programs

Concord Medical Officially Opens New Specialty Cancer Hospital in Guangzhou

BEIJING, June 11, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone ...

2021-06-11 18:11 14367

Viraleze registered for sale in Covid-ravaged India

MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country. The announcement...

2021-06-11 15:15 13742

Viraleze registered for sale in Covid-ravaged India

MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country. The announcement...

2021-06-11 15:03 2007

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based inOsaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test conducte...

2021-06-11 14:00 2378

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based inOsaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test conducte...

2021-06-11 14:00 2904